UNSPSC 85372201: Diagnosis of hydroxyapatite deposition disease

This classification denotes the group of activities that yields a diagnosis of Hydroxyapatite deposition disease. Hydroxyapatite deposition disease is listed in the World Health Organization's International Statistical Classification of Diseases and Related Health Problems or ICD-10 as a four digit category under code M11. 0

UNSPSC 85372201 Diagnosis of hydroxyapatite deposition disease is a Commodity code that shows minimal alignment between its nominal scope and the state and local procurement activity tagged under it. The three recent opportunities posted under this code cover diagnostic imaging systems architecture and integration (San Mateo Medical Center's PACS implementation), school-based special education contracted services (Birdville Independent School District), and temporary health professional staffing across ancillary clinical categories (Santa Clara County Health System). None of these solicitations address hydroxyapatite deposition disease diagnosis specifically. The code appears to be misapplied by the issuing bodies, as the opportunities reflect broader health-system infrastructure, education services, and clinical staffing rather than a specific diagnostic discipline.

The issuing bodies span county health systems, independent school districts, and public hospitals across California and Texas. San Mateo Medical Center (a county public hospital system) solicited enterprise-grade PACS implementation with EPIC integration on an RFP basis with a due date of October 21, 2026; Santa Clara County Health System established a non-exclusive qualified vendor pool for temporary ancillary health professional staffing (including diagnostic imaging and audiology categories) with an October 7, 2026 response date; and Birdville Independent School District (northeast Tarrant County) requested sealed proposals for special education contracted services including audiologist and vision evaluation services with an October 21, 2026 deadline. The code does not reflect coherent recent procurement demand around hydroxyapatite deposition disease diagnosis and warrants re-evaluation for proper UNSPSC classification.